ArQule, Inc. (ARQL) Insider Value Fund L. P. Biotechnology Sells 2,301,581 Shares

ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 2,301,581 shares of ArQule stock in a transaction on Wednesday, April 4th. The stock was sold at an average price of $2.90, for a total transaction of $6,674,584.90. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

ARQL opened at $2.79 on Friday. ArQule, Inc. has a 1-year low of $0.92 and a 1-year high of $3.35. The company has a quick ratio of 4.98, a current ratio of 4.98 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $250.88, a price-to-earnings ratio of -7.15 and a beta of 0.83.

How to Become a New Pot Stock Millionaire

ArQule (NASDAQ:ARQL) last posted its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). During the same quarter in the prior year, the company earned ($0.10) earnings per share. equities analysts predict that ArQule, Inc. will post -0.31 earnings per share for the current year.



Institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC bought a new stake in ArQule in the fourth quarter valued at $165,000. Northern Trust Corp increased its stake in ArQule by 0.9% in the second quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 1,385 shares in the last quarter. Virtu Financial LLC increased its stake in ArQule by 343.8% in the fourth quarter. Virtu Financial LLC now owns 129,038 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 99,964 shares in the last quarter. Deutsche Bank AG bought a new stake in ArQule in the fourth quarter valued at $390,000. Finally, Point72 Asset Management L.P. bought a new stake in ArQule in the third quarter valued at $2,220,000. 67.08% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages recently weighed in on ARQL. Leerink Swann raised shares of ArQule from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 5th. Zacks Investment Research downgraded shares of ArQule from a “buy” rating to a “hold” rating in a research note on Wednesday, April 4th. BidaskClub downgraded shares of ArQule from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 7th. B. Riley set a $4.00 target price on shares of ArQule and gave the stock a “buy” rating in a research note on Monday, March 26th. Finally, ValuEngine raised shares of ArQule from a “sell” rating to a “hold” rating in a research note on Thursday, March 15th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. ArQule presently has an average rating of “Buy” and a consensus price target of $4.08.

COPYRIGHT VIOLATION NOTICE: “ArQule, Inc. (ARQL) Insider Value Fund L. P. Biotechnology Sells 2,301,581 Shares” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://stocknewstimes.com/2018/04/15/value-fund-l-p-biotechnology-sells-2301581-shares-of-arqule-inc-arql-stock.html.

About ArQule

ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer.

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply